Market Closed -
Japan Exchange
02:00:00 2024-05-08 EDT
5-day change
1st Jan Change
2,728
JPY
-0.04%
-0.18%
-6.74%
DyDo Group Holdings, Inc. signed an agreement to acquire WOSANA S.A. for PLN 197.58 million.
DyDo Group Holdings, Inc. (TSE:2590) signed an agreement to acquire WOSANA S.A. for PLN 197.58 million on December 21, 2023.
DyDo Group Holdings, Inc. Reports Sales Results for the Month from March 21, 2024 to April 20, 2024 and Year to Date from January 21, 2024 to April 20, 2024
04-30
CI
DyDo Group Disposes 17.67 Million Worth of Shares as Restricted Stock Compensation
04-16
MT
DyDo Sets Up Nominating and Compensation Committee
04-16
MT
DyDo Group Holdings, Inc. Announces Committee Changes
04-16
CI
DyDo Group Holdings to Book 4.5 Billion Yen From Gain on Sale of Investment
04-02
MT
DyDo Group Holdings, Inc. Reports Sales Results for the Month from February 21, 2024 to March 20, 2024 and Year to Date from January 21, 2024 to March 20, 2024
03-29
CI
DyDo Group Holdings, Inc. Reports Monthly Sales Results for the Month from January 21, 2024 to February 20, 2024
02-29
CI
DyDo Group Holdings, Inc. completed the acquisition of WOSANA S.A. from Avallon MBO II managed by Avallon Sp. z o.o.
02-28
CI
Dydo Group Holdings, Inc. Revises Consolidated Financial Forecasts for the Year Ending January 20, 2024
02-15
CI
DyDo Group Holdings, Inc. Reports Sales Results for the Month from December 21, 2023 to January 20, 2024 and Year to Date from January 21, 2023 to January 20, 2024
01-31
CI
Dydo's Sales Gains 29.2% in Final Two Months of Fiscal Year
12-29
MT
DyDo Group Holdings, Inc. Reports Sales Results for the Month from November 21, 2023 to December 20, 2023 and Year to Date from January 21, 2023 to December 20, 2023
12-29
CI
DyDo Group to Acquire Polish Soft Drink Manufacturer for Over 7 Billion Yen
12-22
MT
DyDo Group Holdings, Inc. signed an agreement to acquire WOSANA S.A. for PLN 197.58 million.
12-20
CI
Dydo Group Unit Files New Drug Application for Autoimmune Disease Treatment Candidate
12-19
MT
Catalyst Pharmaceuticals Partner Submits New Drug Application for Neuromuscular Disorder Treatment in Japan
12-18
MT
DyDo Group Holdings, Inc. Reports Sales Results for the Month from October 21, 2023 to November 20, 2023 and Year to Date from January 21, 2023 to November 20, 2023
11-30
CI
DyDo Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Year Ending January 2024
11-27
CI
DyDo Group Holdings, Inc. Announces Preliminary Sales Results for the Month and Year to Date Ended October 20, 2023
23-10-31
CI
DyDo Group Holdings, Inc. Announces Sales Results for the Month and Year to Date Ended August 20, 2023
23-08-31
CI
DyDo Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 20, 2024
23-08-28
CI
Dydo Group Holdings, Inc. Reports Sales Results for the Month from June 21, 2023 to July 20, 2023 and Year to Date From January 21, 2023 to July 20, 2023
23-07-31
CI
DyDo Group Holdings, Inc. Reports Sales Results for the Month from May 21, 2023 to June 20, 2023 and Year to Date from January 21, 2023 to June 20, 2023
23-06-30
CI
DyDo Group Holdings, Inc. Reports Sales Results for the Month from April 21, 2023 to May 20, 2023 and Year to Date from January 21, 2023 to May 20, 2023
23-05-31
CI
DyDo Group Holdings, Inc. Reports Earnings Results for the First Quarter Ended April 20, 2023
23-05-26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
DyDo Group Holdings, Inc., formerly DyDo DRINCO, INC. is a Japan-based company mainly engaged in the manufacture and sale of beverages. The Company operates through three business segments. The Beverage Sales segment is involved in the planning, development and sale of various soft drinks to consumers through convenience stores and vending machines. Through a consolidated subsidiary, this segment is also engaged in the manufacture and sale of drinkable preparations such as quasi drugs. The Contract Drink Manufacturing segment is engaged in the contract manufacture of drinkable preparations, including drugs and medicines, quasi drugs, as well as soft drinks. The Foods Manufacture and Sale segment is involved in the manufacture and sale of fruit jellies.
More about the company
Last Close Price
2,728
JPY
Average target price
3,000
JPY
Spread / Average Target
+9.97%
Consensus
1st Jan change
Capi.
-6.74% 555M +6.60% 270B +1.07% 45.83B +21.54% 22.47B +40.96% 17.93B -10.72% 16.57B +17.66% 12.26B +0.83% 11.33B +11.55% 10.41B +2.70% 9.46B
Other Non-Alcoholic Beverages
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1